Cannabis herbal medicine to be tested for ‘dysmenorrhea’

The European Union is considering testing herbal remedies to prevent the spread of the bacterial dysmenorrhoea that has killed more than 4,000 people in the European Union in recent months.

“We are currently assessing the clinical potential of these herbal medicines for use as antiretroviral therapy (ART) therapies in clinical trials, and the potential of introducing them into Europe to reduce the risk of human-to-human transmission of the human coronavirus,” a spokesman for the European Medicines Agency said.

Drugmakers are testing herbal products for the bacterial disease which has killed at least 1,400 people in Europe since October, when a new strain of the coronaviruses variant Mycobacterium avium-19 was discovered in the Netherlands.

The latest figures show more than 1,300 people have died of the disease since it was discovered, which has forced the European Commission to declare a public health emergency in many European countries.

In response to the coronovirus pandemic, the EU has been considering introducing herbal products containing ingredients from botanical plants and animals.

These will be tested by the European Food Safety Authority (EFSA), a group of 28 EU countries, as part of the wider effort to ensure there is no risk to public health.

At the heart of the idea is the belief that cannabis and its active ingredient tetrahydrocannabinol (THC) are more effective than their conventional counterparts for the treatment of the condition.

There are also growing concerns about the potential risks of the drug to those with HIV and other chronic conditions, such as hepatitis C. Some of the medicines are being tested by pharmaceutical giant AstraZeneca for the prevention of HIV.